Dopamine transporter methamphetamine

Kokoshka, J.M., Vaughan, R.A., Hanson, G.R., Fleckenstein, A.E. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur. J. Pharmacol. 361 269, 1998. 

Metzger, R.R., Haughey, H.M., Wilkins, D.G. et al. Methamphetamine-induced rapid decrease in dopamine transporter function role of dopamine and hyperthermia. J. Pharmacol. Exp. Ther. 295 1077, 2000. 

Volkow, N.D., Chang, L., Wang, G.J. et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry. 158 377, 2001. 

McCann, U.D., Wong, D.F., Yokoi, F. et al. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users evidence from positron emission tomography studies with [llC]WIN-35,428../. Neurosci. 18 8417, 1998. 

Sekine, Y., Iyo, M., Ouchi, Y. et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am. J. Psychiatry. 58 1206, 2001. 

The most commonly used agents to enhance attention in attention deficit disorder are the stimulants methylphenidate and ( -amphetamine. Other effective stimulants are not as widely used, pemoline because of liver toxicity and methamphetamine because of its greater abuse potential. Methylphenidate and ( -amphetamine act predominantly by releasing dopamine from presynaptic dopamine terminals (Figs. 12— 2 and 12—3). These agents not only block the dopamine transporter but may actually... 

Methamphetamine and MDMA have been shown to cause damage to dopamine transporters. Anecdotally, users of both these drugs refer to the hardships of coming down and the hangover typified by fatigue and depression that typically lasts several days. 

Volkow, N., L. Chang, G. Wang, et al. Association of Dopamine Transporter Reduction with Psychomotor Impairment in Methamphetamine Abusers. The American Journal of Psychiatry 3 (March 2001) 377-382. 

Methamphetamine (MAP) is a psychostimulant that induces enhanced arousal and euphoria acutely, and psychosis and addiction chronically. MAP enters the terminals/neuron via the monoamine transporters (dopamine transporter DAT, serotonin transporter SERT, or norepinephrine transporter NET), displaces... 

Fukushima, S., Shen, H., Hata, H., Ohara, A., Ohmi, K., Ikeda, K., Numachi, Y., Kobayashi, H., Hall, F. S., Uhl, G. R., and Sora, I. (2007). Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Pychopharmacologp (Berl.) 193, 55-62. 

Fig. 14. In vivo PET images from Volkow et al. (2001a) of the distribution volume of [llC]d-threo-methylphenidate (label dopamine transporter sites) in a control and a methamphetamine abuser. The images represent the level of the striatum (left) and the cerebellum (right) in a normal control and a methamphetamine abuser evaluated twice, during short and protracted abstinence. Note the reduction of striatal dopamine transporter binding following early abstinence and the reversal to more normal levels in binding in the methamphetamine abuser with protracted abstinence.

Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J (2001a) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 27 9414-9418. 

Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Mori N. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003 160 1699-701. 

Hashimoto S, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Shimizu E, Iyo M. Protective effects of N-acetylcysteine on the reduction of dopamine transporters in the striatum of the monkeys treated with methamphetamine. Neuropsychopharmacology 2004 29 2018-13. 

Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Sora I, Iyo M, Katsu T, Nomura A, Nakata K, Oyaki N. Nine or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 2003 3 242-7. 

Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG. 1998. Role of dopamine transporter in methamphetamine-induced neurotoxicity evidence from mice lacking the transporter. J. Neurosci. 18 4861-69... 

---